The stock of Pliant Therapeutics Inc (NASDAQ: PLRX) has increased by 13.35% when compared to last closing price of $1.19.Despite this, the company has seen a gain of 15.29% in its stock price over the last five trading days. globenewswire.com reported 2025-06-27 that Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF).
Is It Worth Investing in Pliant Therapeutics Inc (NASDAQ: PLRX) Right Now?
The 36-month beta value for PLRX is at 1.41. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 10 as “hold,” and 0 as “sell.”
The public float for PLRX is 54.04M, and currently, shorts hold a 6.23% of that float. The average trading volume for PLRX on July 09, 2025 was 1.14M shares.
PLRX’s Market Performance
PLRX’s stock has seen a 15.29% increase for the week, with a -17.25% drop in the past month and a 7.91% gain in the past quarter. The volatility ratio for the week is 8.11%, and the volatility levels for the past 30 days are at 8.44% for Pliant Therapeutics Inc The simple moving average for the past 20 days is 3.37% for PLRX’s stock, with a -81.07% simple moving average for the past 200 days.
PLRX Trading at -3.37% from the 50-Day Moving Average
After a stumble in the market that brought PLRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.62% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PLRX starting from Coulie Bernard, who sale 52,419 shares at the price of $11.20 back on Jan 17 ’25. After this action, Coulie Bernard now owns 430,517 shares of Pliant Therapeutics Inc, valued at $587,150 using the latest closing price.
Cummings Keith Lamont, the Chief Financial Officer of Pliant Therapeutics Inc, sale 20,148 shares at $11.20 during a trade that took place back on Jan 17 ’25, which means that Cummings Keith Lamont is holding 262,608 shares at $225,680 based on the most recent closing price.
Stock Fundamentals for PLRX
The total capital return value is set at -0.74. Equity return is now at value -63.22, with -50.67 for asset returns.
Based on Pliant Therapeutics Inc (PLRX), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -2.89. The debt to equity ratio resting at 0.23. The interest coverage ratio of the stock is -69.54.
Currently, EBITDA for the company is -228.37 million with net debt to EBITDA at 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.03.
Conclusion
In conclusion, Pliant Therapeutics Inc (PLRX) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
